Prolonged Oral Levofloxacin-Rifampin for Staphylococcus Aureus Prosthetic Joint Infection (PJI) Treated With Debridement And Retention Of Components: A Prospective Observational Cohort Study. Mayo PJI Study Group (MPSG).

Trial Profile

Prolonged Oral Levofloxacin-Rifampin for Staphylococcus Aureus Prosthetic Joint Infection (PJI) Treated With Debridement And Retention Of Components: A Prospective Observational Cohort Study. Mayo PJI Study Group (MPSG).

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 May 2015

At a glance

  • Drugs Levofloxacin; Rifampicin
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Feb 2010 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top